QT Imaging Receives New CPT Code for 3D Breast Ultrasound Tomography

The American Medical Association’s (AMA) CPT (Current Procedural Terminology) Editorial Panel has approved a new Category III CPT code for 3D quantitative transmission volumetric ultrasound breast tomography.

The new Category III code—X579T—represents a significant milestone in the clinical and commercial advancement of QT Imaging Holding Inc.’s technology, recognizing the clinical service enabled by its radiation-free, compression-free, 3D breast imaging platform, company executives said. The new CPT code ensures standardized reporting of this imaging service, supporting data collection, utilization tracking, and continued evaluation by clinicians, payers, and health systems. The code is scheduled to be released on July 1 this year and take effect on Jan. 1, 2027.

“Approval of our first CPT code is a meaningful validation of both the technology and its clinical foundation and significantly enhances our commercial strategy in particular to prospective hospital accounts,” QT Imaging CEO Dr. Raluca Dinu said. “This milestone reflects years of rigorous development, clinical engagement, and collaboration with the medical community. It is an important step toward expanding access to a safer, more comfortable breast imaging option that complements existing modalities and supports better-informed clinical decision making.”

Category III CPT codes are established by the AMA to track emerging technologies and services that demonstrate clinical relevance and growing adoption. Acceptance of a Category III code signals acknowledgment by the CPT Editorial Panel that a technology represents a distinct and reportable clinical service, and is a major step on the pathway toward broader reimbursement and adoption.

“We plan to continue working closely with clinical partners, professional societies, and regulatory stakeholders to advance adoption of our technology, as well as to pursue additional CPT codes,” Dr. Dinu added.

QT Imaging’s system uses advanced ultrasound tomography to produce 3D breast volumetric images without ionizing radiation or painful compression. The technology is designed to provide quantitative, reproducible information that can be particularly valuable in women with dense breast tissue, while improving the overall patient experience.

QT Imaging Holdings is a public medical device company engaged in research, development, and commercialization of body imaging systems using low-frequency sound waves. The company’s strategy is predicated upon the fact that medical imaging is critical to disease detection, diagnosis, and treatment, and that it should be safe, affordable, accessible, and centered on the patient’s experience.